Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 2/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443418 | 0.78 | AHR (0.74) | ESR2CYP1A2AHRERCC5FEN1 | |
| SCHEMBL10391765 | 0.78 | ALDH1A1 (0.47) | ESR2CYP1A2ALOX5MEN1KMT2A | |
| SCHEMBL29493845 | 0.78 | AHR (0.74) | ESR2CYP1A2AHRERCC5FEN1 | |
| SCHEMBL24285830 | 0.77 | ESR2 (0.52) | ESR2CYP1A2AHRERCC5FEN1 | |
| SCHEMBL19785362 | 0.76 | ESR2 (0.56) | ESR2CYP1A2AHRERCC5FEN1 | |
| Water SCHEMBL11023201 | 0.76 | AHR (0.70) | ESR2CYP1A2AHRERCC5FEN1 | |
| SCHEMBL26428597 | 0.76 | AHR (0.46) | ESR2CYP1A2AHRMEN1KMT2A | |
| SCHEMBL29778098 | 0.74 | CYP2A6 (0.58) | ESR2CYP1A2AHRERCC5FEN1 | |
| SCHEMBL20955807 | 0.74 | CYP2A6 (0.58) | ESR2CYP1A2AHRERCC5FEN1 | |
| SCHEMBL22544432 | 0.74 | CYP2A6 (0.58) | ESR2CYP1A2AHRERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305792-B1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME | LG CHEMICAL LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| US-10580998-B2 | Nitrogen-containing condensed cyclic compound and organic light emitting device using same | LG CHEM, LTD. (KR) | 2020-03-03 | — | — | US | disclosed |
| US-10347845-B2 | Nitrogen-containing condensed cyclic compound and organic light emitting device using same | LG CHEM, LTD. (KR) | 2019-07-09 | — | — | US | disclosed |
| US-20190173022-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LG CHEM, LTD. (KR) | 2019-06-06 | — | — | US | disclosed |
| EP-3305792-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME | LG Chem, Ltd. (KR) | 2018-04-11 | — | — | EP | disclosed |
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LG CHEM, LTD. (KR) | 2017-07-27 | — | — | US | disclosed |
| EP-2614053-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012033225-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10580998-B2 | Nitrogen-containing condensed cyclic compound and organic light emitting device using same | CRY1, NOS1, NOLC1 | ESR2 981/4885CYP1A2 667/4885AHR 1658/4885 |
| US-20190173022-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | CRY1, NOS1, NOLC1 | ESR2 981/4885CYP1A2 667/4885AHR 1658/4885 |
| US-10347845-B2 | Nitrogen-containing condensed cyclic compound and organic light emitting device using same | CRY1, NOS1, NOLC1 | ESR2 981/4885CYP1A2 667/4885AHR 1658/4885 |
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | CRY1, NOS1, NOLC1 | ESR2 981/4885CYP1A2 667/4885AHR 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.